Extended indication Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II
Therapeutic value No judgement

Product

Active substance Veliparib
Domain Oncology and Hematology
Main indication Ovarian cancer
Extended indication Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage III or IV high-grade - first-line with carboplatin and paclitaxel.
Manufacturer Abbvie
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 66

Market share is generally not included unless otherwise stated.

References NKR
Additional remarks Hoog stadium (FIGO III en IV) ovariumcarcinoom, hooggradig sereus, behandeld met o.a. chemotherapie in de eerste lijn. Selectie uit NKR: 1316 patiƫnten over in 2014 en 2015. Schatting: 10% BRCA1 in de populatie (gebaseerd op de literatuur en praktijk).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.